[Intratympanic gentamicin in Menière's disease].
OBJECTIVE
To investigate the effect and toxicity of intratympanic gentamicin injection therapy for intractable vertigo of Menière's disease.


METHODS
Thirteen patients diagnosed of unilateral Menière's disease were given gentamicin 0.5 ml (26.7 mg/ml) intratympanically once a week for two weeks. All the patients were followed-up for at least two years. The result was monitored using the criteria set by Chinese Otorhinolaryngological Academy and Editorial Board of Chinese Journal of Otorhinlolaryngology in 1996.


RESULTS
Complete or substantial vertigo control was achieved in 12 patients (92.3%). Two weeks after treatment, the pure tone (0.5 kHz, 1.0 kHz, 2.0 kHz, 3.0 kHz) average hearing threshold had no significant change. 8.0 kHz hearing threshold increased significantly in 3 patients(23.1%). 18-24 months after treatment, the hearing threshold increased significantly in 9 patients respectively. No patient felt improved in tinnitus.


CONCLUSIONS
Intratympanic gentamicin injection is a simple and cost-effective means for controlling intractable vertigo spelling of Menière's disease, but it also has some toxic effect to hearing.
Huang
Weining
W
Department of Otorhinolaryngology, Beijing Hospital, Ministry of Health, Beijing, 100730, China.
Xu
Huijie
H
Gao
Bo
B
D000328:Adult; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D004432:Ear, Middle; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007267:Injections; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D014717:Vertigo / Q000188:drug therapy / Q000209:etiology
D005839:Gentamicins